|
Session 128-Poster Abstracts
Hepatitis C Therapy: ART Interactions
Wednesday, 2-4 pm; Poster Hall |
659
 |
Fast Liver Damage Progression in HIV/HCV Co-infected Patients in Spite of Effective HAART
Juan Macías*1, M von Wichmann2, A Rivero3, F Tellez4, D Merino5, M Márquez6, A Vergara7, M Delgado8, J Iribarren2, and J Pineda1
1Hosp Univ de Valme, Seville, Spain; 2Hosp de Donostia, San Sebastian, Spain; 3Hosp Univ Reina Sofia, Cordoba, Spain; 4Hosp de la Linea, Cadiz, Spain; 5Hosp Juan Ramon Jimenez, Huelva, Spain; 6Hosp Univ Virgen de la Victoria, Malaga, Spain; 7Hosp Univ Puerto Real, Cadiz, Spain; and 8Hosp Univ Carlos Haya, Malaga, Spain |
660
|
Biomarkers of Inflammation and Coagulation and Risk of Non-AIDS Death in HIV/Hepatitis Co-infected Patients in the SMART Study
Lars Peters and for the INSIGHT SMART Study Group
Copenhagen HIV Prgm, Denmark |
661
|
Genetic Variability of the HCV NS3 Protease in HIV/HCV Co-infected Patients Treated with HIV Protease Inhibitors
Marcelle Bottecchia*, A Madejon, M Sanchez-Carrillo, P Labarga, J García-Samaniego, and V Soriano
Hosp Carlos III, Madrid, Spain |
662
|
Hepatic Safety and Efficacy of Raltegravir in Patients Co-infected with HIV and HBV or HCV
Jurgen Rockstroh*1, H Teppler2, J Zhao2, P Sklar2, C Harvey2, R Leavitt2, and B-Y Nguyen2
1Univ of Bonn, Germany and 2Merck Res Labs, North Wales, PA, US |
663
|
Effect of Accompanying Antiretroviral Drugs on Virologic Response to PEG-IFN and Ribavirin in HIV/HCV Co-infected Patients
Juan Berenguer*1, M von Wichmann2, C Quereda3, P Miralles1, J Mallolas4, J López Aldeguer5, J Álvarez Pellicer6, J De Miguel7, J Bellón1, J González-García6, and GESIDA 36/03 and 50/06 Study Groups
1Hosp Gen Univ Gregorio Marañón, Madrid, Spain; 2Hosp Donostia, Spain; 3Hosp Ramon y Cajal, Spain; 4Hosp Clin, Barcelona, Spain; 5Hosp Univ La Fe, Valencia, Spain; 6Hosp Univ La Paz, Madrid, Spain; and 7Hosp Principe de Asturias, Spain |
| 664 |
Impact of Zidovudine on Hematologic Parameters during Treatment with Peginterferon alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV/HCV Co-infected Patients Enrolled in a Large Randomized Double-blind Study
M Rodriguez-Torres1, Jihad Slim*2, L Bhatti3, R Sterling4, M Sulkowski5, T Hassanein6, B Clotet7, T Branco8, S Passe9, S Stancic9, and the PARADIGM Study Investigators
1Fndn de Investigación de Diego, Santurce, Puerto Rico; 2St Michael’s Med Ctr, Newark, NJ, US; 3AIDS Hlthcare Fndn, Los Angeles, CA, US; 4Virginia Commonwealth Univ, Richmond, US; 5Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 6Univ of California, San Diego, US; 7Fndn irsiCaixa, Hosp Univ Germans Trias i Pujol, Badalona, Spain; 8Hosp Fernando da Fonseca, Amadora, Portugal; and 9Roche, Nutley, NJ, US |
|
